EUDA Health Holdings Limited Repurchases and Cancels Streeterville Warrant, Strengthening Capital Structure

SINGAPORE — March 4, 2026 — EUDA Health Holdings Limited (NASDAQ: EUDA), a Singapore-based healthcare company focused on non-invasive and preventive medical services in Asia, has announced the full repurchase and cancellation of a warrant previously issued to Streeterville Capital, LLC. The move removes the possibility of issuing up to 2,000,000 new ordinary shares, a step that the company says simplifies its capital structure and eliminates a potential source of shareholder dilution.

The repurchase transaction was completed on February 27, 2026, with EUDA paying a total of US$125,000 to buy back the warrant from the investor. Following the repurchase, the warrant was officially cancelled and is no longer outstanding, meaning that no shares can be issued under that agreement going forward. This development marks an important financial and strategic update for the company as it continues expanding its healthcare operations across Asia.

Background of the Streeterville Warrant Agreement

Initial Securities Purchase Agreement

The warrant originally emerged from a securities purchase agreement dated November 26, 2025. Under this agreement, EUDA Health issued a warrant to an accredited investor associated with Streeterville Capital. The warrant provided the investor with the right to purchase up to 2,000,000 newly issued ordinary shares of EUDA at a predetermined exercise price.

In financial markets, warrants are commonly used as investment incentives. They give investors the option to buy shares in a company at a specified price within a certain period of time. If exercised, warrants can increase the total number of shares outstanding, which may dilute the ownership percentage of existing shareholders.

In EUDA’s case, the warrant was immediately exercisable once issued. This meant the investor could convert the warrant into shares at any time during the exercise period, subject to the terms outlined in the purchase agreement.

Subsequent Amendments to the Warrant

After the original issuance in November 2025, the warrant agreement underwent two amendments. The first amendment occurred on December 16, 2025, followed by a second amendment on January 13, 2026. These amendments adjusted certain provisions related to the warrant’s terms and conditions.

Such amendments are common in financial agreements, especially when companies and investors renegotiate conditions to reflect market dynamics, share price movements, or strategic considerations. However, despite these modifications, the warrant remained capable of converting into up to two million ordinary shares.

Until its repurchase in February 2026, the warrant represented a potential future issuance of shares that could affect the company’s capitalization.

Repurchase and Cancellation of the Warrant

Transaction Details

EUDA Health confirmed that on February 27, 2026, it completed the full repurchase of the Streeterville warrant for US$125,000. The payment allowed the company to regain control of the warrant instrument and immediately cancel it.

Once cancelled, the warrant ceased to exist as a financial instrument. This means the investor no longer has any rights to purchase shares under that agreement, and the company no longer faces the possibility of issuing shares tied to that warrant.

The transaction effectively eliminated a potential issuance of up to 2,000,000 ordinary shares, thereby removing a possible dilution risk for existing shareholders.

Impact on Share Structure

The cancellation of the warrant has several implications for EUDA’s capital structure. By eliminating the warrant, the company has reduced the number of potential shares that could enter circulation in the future.

This action benefits the company’s financial framework in multiple ways:

• Reduced dilution risk for current shareholders.
• Improved transparency in the company’s share structure.
• Greater flexibility in planning future financing activities.
• Enhanced investor confidence through proactive capital management.

For public companies listed on stock exchanges such as Nasdaq, managing dilution risk is a key concern. When warrants or convertible instruments are outstanding, investors often consider the possibility that new shares could enter the market, potentially lowering the value of existing shares. Removing such instruments can therefore help strengthen investor perception of the company’s financial discipline.

Strategic Significance for EUDA Health

Capital Structure Simplification

The repurchase of the Streeterville warrant reflects EUDA Health’s broader strategy to streamline its capital structure. By eliminating the warrant, the company now has no remaining warrants under the November 2025 agreement.

This simplification allows management to focus on operational growth and strategic expansion without the uncertainty associated with potential share conversions.

Alignment With Growth Initiatives

EUDA Health has been actively expanding its healthcare platform across Asia, particularly in the rapidly growing sectors of preventive medicine and longevity science. The company’s initiatives include the development of stem-cell related medical services, wellness programs, and innovative healthcare platforms.

By resolving outstanding financial instruments such as warrants, EUDA positions itself to pursue new investments, partnerships, and acquisitions without additional complexity in its equity structure.

Overview of EUDA Health Holdings Limited

Company Profile

EUDA Health Holdings Limited is a Singapore-based healthcare provider specializing in non-invasive medical solutions. The company operates across several Asian markets, including Singapore, Malaysia, and China.

Its business model focuses on delivering healthcare services that emphasize prevention, longevity, and wellness. Rather than relying solely on traditional medical treatments, EUDA integrates advanced technologies and modern healthcare approaches to improve long-term health outcomes.

Focus on Preventive and Longevity Healthcare

The company has identified the longevity sector as a major opportunity for growth. As populations across Asia age rapidly, demand for preventive healthcare services continues to rise.

EUDA aims to position itself as a leader in this emerging industry by offering services such as:

• Non-invasive diagnostic testing
• Personalized wellness programs
• Longevity and anti-aging treatments
• Advanced medical technology platforms

These offerings are designed to help individuals maintain health and vitality as they age.

Demographic Trends Driving Demand

Rapid Population Aging in Asia

One of the key factors behind EUDA’s growth strategy is the demographic transformation occurring across Asia. The region is home to more than 1.8 billion people, and a significant portion of the population is entering older age groups.

In many Asian countries, projections show that more than 30% of the population will soon be over the age of 60. This shift creates enormous demand for healthcare services that focus on prevention and longevity rather than simply treating illness.

Growing Demand for Preventive Medicine

Preventive healthcare has become a major focus worldwide. Instead of waiting for diseases to develop, healthcare providers increasingly emphasize early detection, lifestyle management, and personalized treatment plans.

EUDA’s strategy aligns with this global trend. By developing healthcare platforms that combine diagnostics, wellness services, and longevity research, the company seeks to serve the evolving needs of aging populations.

Recent Financial and Corporate Developments

Capital Raising Activities

In addition to the warrant repurchase, EUDA Health recently completed a share offering that raised approximately $3.75 million in gross proceeds. The offering involved the sale of 12,500,000 ordinary shares to accredited investors.

The company stated that the funds will be used for general corporate purposes, including potential acquisitions, business expansion, and working capital.

Strengthening Financial Position

By raising capital while also removing the warrant overhang, EUDA is taking steps to strengthen its financial foundation. The combination of new funding and a cleaner capital structure may allow the company to pursue growth opportunities more effectively.

Investors typically view these kinds of financial adjustments as signals that a company is actively managing its balance sheet and planning for long-term stability.

Understanding Warrants and Share Dilution

What Is a Warrant?

A warrant is a financial instrument that gives the holder the right, but not the obligation, to purchase a company’s shares at a predetermined price before a specified expiration date.

Warrants are often used in investment deals as incentives for investors. If the company’s share price rises above the warrant’s exercise price, the holder may exercise the warrant to purchase shares at a discount.

Why Companies Repurchase Warrants

Companies sometimes choose to repurchase and cancel outstanding warrants for several reasons:

• To reduce future share dilution.
• To simplify their capital structure.
• To improve investor confidence.
• To prepare for future financing activities.

EUDA’s decision to buy back the Streeterville warrant reflects these common motivations.

Market and Investor Perspective

Potential Benefits for Shareholders

From an investor perspective, the removal of the warrant may be viewed positively because it eliminates the possibility that millions of additional shares could enter the market.

When potential dilution is removed, existing shareholders maintain their ownership percentage more securely. This can help stabilize investor sentiment and improve confidence in the company’s financial management.

Focus on Long-Term Growth

With the warrant cancelled, EUDA can now focus on executing its long-term strategy in healthcare innovation and market expansion. Investors will likely watch closely to see how the company deploys its capital and whether it can capture opportunities in Asia’s growing longevity market.

Future Outlook

EUDA Health’s repurchase and cancellation of the Streeterville warrant marks another step in the company’s evolving corporate strategy. By eliminating the warrant, the company has removed a potential source of share dilution and strengthened its capital structure.

At the same time, EUDA continues to invest in healthcare technologies and services aimed at improving longevity and preventive care. With demographic trends strongly favoring the healthcare sector, the company is positioning itself to meet the growing demand for advanced medical solutions across Asia.

As the region’s population continues to age, companies like EUDA that focus on preventive medicine, wellness, and longevity science may play an increasingly important role in shaping the future of healthcare.

#EUDAHealth #NasdaqEUDA #HealthcareIndustry #LongevityHealthcare #SlimScan #GrowthStocks #CANSLIM